報價延遲最少15分鐘:2025/06/02 21:35 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.5 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
--/-0.81
|
|
企業價值
4.38M
|
| 資產負債 |
|
每股賬面淨值
4.35
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
658.00K
|
|
每股收益
0.52
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 21:35 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services. |